Document and Entity Information - USD ($) $ in Millions |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2025 |
Apr. 15, 2026 |
Jun. 30, 2025 |
|
| Registrant Name | MEDICUS PHARMA LTD. | ||
| Registrant CIK | 0001997296 | ||
| Current Fiscal Year End Date | --12-31 | ||
| Document Type | 10-K/A | ||
| Document Annual Report | true | ||
| Entity File Number | 001-42408 | ||
| Document Financial Statement Error Correction [Flag] | false | ||
| Document Period End Date | Dec. 31, 2025 | ||
| Document Fiscal Year Focus | 2025 | ||
| Document Fiscal Period Focus | FY | ||
| Entity Incorporation, State or Country Code | A6 | ||
| Entity Tax Identification Number | 98-1778211 | ||
| Entity Address, Address Line One | 300 Conshohocken State Rd. | ||
| Entity Address, City or Town | W. Conshohocken | ||
| Entity Address, State or Province | PA | ||
| Entity Address, Postal Zip Code | 19428 | ||
| City Area Code | 610 | ||
| Local Phone Number | 636-0184 | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Voluntary Filers | No | ||
| Entity Current Reporting Status | Yes | ||
| Entity Interactive Data Current | Yes | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Small Business | true | ||
| Entity Emerging Growth Company | true | ||
| Entity Shell Company | false | ||
| Entity Public Float | $ 28.3 | ||
| Entity Common Stock, Shares Outstanding | 41,818,092 | ||
| Amendment Flag | true | ||
| Amendment Description | Medicus Pharma Ltd. (the "Company") is filing this Amendment No. 1 ("Amendment No. 1") to its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 as filed with the Securities Exchange Commission (the "SEC") on March 25, 2026 (the "Original Form 10-K"), to provide the information required by Part III of Form 10-K. This information was previously omitted from the Original Form 10-K in reliance on the General Instructions to Form 10-K, which permits the information in Part III to be incorporated in Form 10-K by reference from the registrant's definitive proxy statement or included in an amendment to Form 10-K, in either case filed with the SEC no later than 120 days after the end of the fiscal year. Pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this Amendment No. 1 also contains new certifications pursuant to Sections 302 and 906 of the Sarbanes-Oxley Act of 2002, which are being filed and furnished, respectively, as exhibits to this Amendment No. 1 under Item 15 of Part IV. Because this Amendment No. 1 does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K under the Exchange Act, paragraphs 4 and 5 of the Section 302 certifications have been omitted. As a result, Item 15 of Part IV has been amended to reflect the filing and furnishing of these new certifications. Except as otherwise expressly noted herein, this Amendment No. 1 does not modify or update in any way the financial position, results of operations, cash flows, or other information contained or incorporated in, including the exhibits thereto, the Original Form 10-K, nor does it reflect events occurring after the filing of the Original Form 10-K. Accordingly, this Amendment No. 1 should be read in conjunction with the Original Form 10-K and with our other filings made with the SEC subsequent to the filing of the Original Form 10-K. In this Amendment No. 1, we provide our website address, www.medicuspharma.com, to disclose that certain information is available on our website. Information contained on, or that can be accessed through, our website is not incorporated by reference into this Amendment No. 1, and references to our website address in this Amendment No. 1 are inactive textual references only. | ||
| Document Transition Report | false | ||
| Entity Ex Transition Period | false | ||
| ICFR Auditor Attestation Flag | false | ||
| Common shares [Member] | |||
| Title of 12(g) Security | Common shares, no par value | ||
| Trading Symbol | MDCX | ||
| Security Exchange Name | NASDAQ | ||
| Warrants [Member] | |||
| Title of 12(g) Security | Warrants, each exercisable for one common share at an exercise price of $4.64 per share | ||
| Trading Symbol | MDCXW | ||
| Security Exchange Name | NASDAQ |